Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
1,076.98
+5.34 (+0.50%)
Official Closing Price
Updated: 1:10 PM EST, Dec 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
99
100
Next >
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
↗
September 16, 2025
The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.
Via
Benzinga
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing
↗
September 16, 2025
Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.
Via
Benzinga
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
↗
September 16, 2025
Via
Stocktwits
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
↗
September 16, 2025
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.
Via
Benzinga
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
↗
September 16, 2025
In an otherwise hot stock market, healthcare stocks are underperforming.
Via
The Motley Fool
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
↗
September 12, 2025
Via
Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
↗
September 12, 2025
Via
Stocktwits
Forecasting The Future: 10 Analyst Projections For Eli Lilly
↗
September 16, 2025
Via
Benzinga
3 Great High-Yield Dividend Stocks to Buy in September
↗
September 16, 2025
Quality yields above 6% from three very different market sectors.
Via
The Motley Fool
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
↗
September 16, 2025
The weight loss drug market may reach $95 billion within five years.
Via
The Motley Fool
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
September 15, 2025
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance....
Via
MarketMinute
Topics
Economy
Intellectual Property
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
↗
September 15, 2025
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.
Via
Benzinga
Topics
Government
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
September 15, 2025
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...
Via
MarketMinute
Topics
Economy
Intellectual Property
Law Enforcement
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
September 15, 2025
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...
Via
MarketMinute
Why Novo Nordisk Stock Popped Today
↗
September 15, 2025
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.
Via
The Motley Fool
1 Stock That Should Be in Every Investor's Portfolio
↗
September 15, 2025
Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.
Via
The Motley Fool
3 Monster Stocks to Hold for the Next 5 Years
↗
September 14, 2025
They could deliver market-beating returns beyond 2030.
Via
The Motley Fool
Topics
Artificial Intelligence
2 Beaten-Down Stocks to Buy and Hold Forever
↗
September 13, 2025
Their prospects look intact despite some recent roadblocks.
Via
The Motley Fool
Topics
Artificial Intelligence
World Trade
This Vanguard ETF Makes It Easy to Invest in the "Magnificent Seven"
↗
September 13, 2025
The "Magnificent Seven" stocks have done incredibly well over the past five years, with six of them more than doubling in value during that time frame.
Via
The Motley Fool
Topics
ETFs
3 No-Brainer Dividend Stocks to Buy in September
↗
September 13, 2025
The attraction of these dividend stocks isn't limited to their dividends.
Via
The Motley Fool
Topics
Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
September 12, 2025
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...
Via
MarketMinute
Topics
Artificial Intelligence
Bankruptcy
Economy
Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case
↗
September 12, 2025
A U.S. appeals court upheld a $183.7 million judgment against Eli Lilly in a whistleblower case, finding the company misreported drug prices and shorted Medicaid rebates.
Via
Benzinga
Topics
Fraud
Whistleblower
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
↗
September 12, 2025
Via
Benzinga
This Under-the-Radar Healthcare Stock Could Soar in 2026
↗
September 12, 2025
We should know a lot more by year-end.
Via
The Motley Fool
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
↗
September 12, 2025
The positives for this big drugmaker appear to outweigh the negatives.
Via
The Motley Fool
Topics
Earnings
Government
World Trade
Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio
↗
September 11, 2025
The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Economy
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
↗
September 11, 2025
One of them is already a leader in the market for weight management drugs, and the other could join this field.
Via
The Motley Fool
Topics
ETFs
Novo Nordisk’s “Employee Diet” Trims Workforce By 9,000
September 11, 2025
Via
AB Newswire
Topics
Economy
Workforce
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally
↗
September 11, 2025
Lilly could launch its GLP-1 pill by this time next year.
Via
The Motley Fool
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
↗
September 11, 2025
A decade from now, you could regret ignoring these no-brainer stock picks.
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.